280 related articles for article (PubMed ID: 33639990)
1. Clinical experience with the AKT1 inhibitor miransertib in two children with PIK3CA-related overgrowth syndrome.
Forde K; Resta N; Ranieri C; Rea D; Kubassova O; Hinton M; Andrews KA; Semple R; Irvine AD; Dvorakova V
Orphanet J Rare Dis; 2021 Feb; 16(1):109. PubMed ID: 33639990
[TBL] [Abstract][Full Text] [Related]
2. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
[TBL] [Abstract][Full Text] [Related]
3. First evidence of a therapeutic effect of miransertib in a teenager with Proteus syndrome and ovarian carcinoma.
Leoni C; Gullo G; Resta N; Fagotti A; Onesimo R; Schwartz B; Kazakin J; Abbadessa G; Crown J; Collins CD; Ranieri C; Scambia G; Zampino G
Am J Med Genet A; 2019 Jul; 179(7):1319-1324. PubMed ID: 31058421
[TBL] [Abstract][Full Text] [Related]
4. The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS).
Suzuki Y; Enokido Y; Yamada K; Inaba M; Kuwata K; Hanada N; Morishita T; Mizuno S; Wakamatsu N
Oncotarget; 2017 Jul; 8(28):45470-45483. PubMed ID: 28525374
[TBL] [Abstract][Full Text] [Related]
5. A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations.
Canaud G; Hammill AM; Adams D; Vikkula M; Keppler-Noreuil KM
Orphanet J Rare Dis; 2021 Jul; 16(1):306. PubMed ID: 34238334
[TBL] [Abstract][Full Text] [Related]
6. Clinical report: one year of treatment of Proteus syndrome with miransertib (ARQ 092).
Biesecker LG; Edwards M; O'Donnell S; Doherty P; MacDougall T; Tith K; Kazakin J; Schwartz B
Cold Spring Harb Mol Case Stud; 2020 Feb; 6(1):. PubMed ID: 32014856
[TBL] [Abstract][Full Text] [Related]
7. Case report: five-year experience of AKT inhibition with miransertib (MK-7075) in an individual with Proteus syndrome.
Ours CA; Sapp JC; Hodges MB; de Moya AJ; Biesecker LG
Cold Spring Harb Mol Case Stud; 2021 Dec; 7(6):. PubMed ID: 34649967
[TBL] [Abstract][Full Text] [Related]
8. Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway.
Yan W; Zhang B; Wang H; Mo R; Jiang X; Qin W; Ma L; Lin Z
Hereditas; 2021 Jun; 158(1):18. PubMed ID: 34074347
[TBL] [Abstract][Full Text] [Related]
9.
Pagliazzi A; Oranges T; Traficante G; Trapani C; Facchini F; Martin A; Semeraro A; Perrone A; Filippeschi C; Giglio S
Front Pediatr; 2021; 9():732836. PubMed ID: 34568242
[No Abstract] [Full Text] [Related]
10. Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome.
Keppler-Noreuil KM; Sapp JC; Lindhurst MJ; Darling TN; Burton-Akright J; Bagheri M; Dombi E; Gruber A; Jarosinski PF; Martin S; Nathan N; Paul SM; Savage RE; Wolters PL; Schwartz B; Widemann BC; Biesecker LG
Am J Hum Genet; 2019 Mar; 104(3):484-491. PubMed ID: 30803705
[TBL] [Abstract][Full Text] [Related]
11. Alpelisib to treat CLOVES syndrome, a member of the PIK3CA-related overgrowth syndrome spectrum.
Garreta Fontelles G; Pardo Pastor J; Grande Moreillo C
Br J Clin Pharmacol; 2022 Aug; 88(8):3891-3895. PubMed ID: 35146800
[TBL] [Abstract][Full Text] [Related]
12. Thrombosis risk factors in PIK3CA-related overgrowth spectrum and Proteus syndrome.
Keppler-Noreuil KM; Lozier J; Oden N; Taneja A; Burton-Akright J; Sapp JC; Biesecker LG
Am J Med Genet C Semin Med Genet; 2019 Dec; 181(4):571-581. PubMed ID: 31490637
[TBL] [Abstract][Full Text] [Related]
13. The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib.
Kobialka P; Sabata H; Vilalta O; Gouveia L; Angulo-Urarte A; Muixí L; Zanoncello J; Muñoz-Aznar O; Olaciregui NG; Fanlo L; Esteve-Codina A; Lavarino C; Javierre BM; Celis V; Rovira C; López-Fernández S; Baselga E; Mora J; Castillo SD; Graupera M
EMBO Mol Med; 2022 Jul; 14(7):e15619. PubMed ID: 35695059
[TBL] [Abstract][Full Text] [Related]
14. Miransertib (ARQ 092), an orally-available, selective Akt inhibitor is effective against Leishmania.
Nandan D; Zhang N; Yu Y; Schwartz B; Chen S; Kima PE; Reiner NE
PLoS One; 2018; 13(11):e0206920. PubMed ID: 30399177
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic and molecular characterization of five patients with PIK3CA-related overgrowth spectrum (PROS).
Gökpınar İli E; Taşdelen E; Durmaz CD; Altıner Ş; Tuncalı T; Martinez-Glez V; Karabulut HG; Vural S; Ceylaner S; Acar MO; Ilgın Ruhi H
Am J Med Genet A; 2022 Jun; 188(6):1792-1800. PubMed ID: 35238469
[TBL] [Abstract][Full Text] [Related]
16. Germline pathogenic variant in PIK3CA leading to symmetrical overgrowth with marked macrocephaly and mild global developmental delay.
Zollino M; Ranieri C; Grossi V; Leoni C; Lattante S; Mazzà D; Simone C; Resta N
Mol Genet Genomic Med; 2019 Aug; 7(8):e845. PubMed ID: 31290289
[TBL] [Abstract][Full Text] [Related]
17. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
Keppler-Noreuil KM; Rios JJ; Parker VE; Semple RK; Lindhurst MJ; Sapp JC; Alomari A; Ezaki M; Dobyns W; Biesecker LG
Am J Med Genet A; 2015 Feb; 167A(2):287-95. PubMed ID: 25557259
[TBL] [Abstract][Full Text] [Related]
18. Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors.
Loconte DC; Grossi V; Bozzao C; Forte G; Bagnulo R; Stella A; Lastella P; Cutrone M; Benedicenti F; Susca FC; Patruno M; Varvara D; Germani A; Chessa L; Laforgia N; Tenconi R; Simone C; Resta N
PLoS One; 2015; 10(4):e0123092. PubMed ID: 25915946
[TBL] [Abstract][Full Text] [Related]
19. [PIK3CA-related overgrowth syndrome (PROS)].
Venot Q; Canaud G
Nephrol Ther; 2017 Apr; 13 Suppl 1():S155-S156. PubMed ID: 28577738
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA activating mutations in facial infiltrating lipomatosis.
Maclellan RA; Luks VL; Vivero MP; Mulliken JB; Zurakowski D; Padwa BL; Warman ML; Greene AK; Kurek KC
Plast Reconstr Surg; 2014 Jan; 133(1):12e-19e. PubMed ID: 24374682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
